Literature DB >> 32032278

Utility of the International HIV Dementia Scale for HIV-Associated Neurocognitive Disorder.

Maria Molinaro1, Ned Sacktor1, Gertrude Nakigozi2, Aggrey Anok2, James Batte2, Alice Kisakye2, Richard Myanja2, Noeline Nakasujja3, Kevin R Robertson4, Ronald H Gray5, Maria J Wawer5, Deanna Saylor1,6.   

Abstract

BACKGROUND: We assessed the utility of the International HIV Dementia Scale (IHDS) in detecting HIV-associated neurocognitive disorder (HAND) in Uganda in antiretroviral (ART)-naïve and ART-experienced adults.
SETTING: A longitudinal observational cohort study in Rakai, Uganda.
METHODS: Three hundred ninety-nine HIV+ ART-naïve adults underwent neurological, functional status, and neuropsychological assessments including the IHDS. Three hundred twelve participants who initiated ART were re-evaluated after 2 years. HAND stages [asymptomatic neurocognitive impairment, mild neurocognitive disorder, and HIV-associated dementia (HAD)] were determined based on Frascati criteria using local normative data. Sensitivity, specificity, and area under the ROC curve were determined for various IHDS thresholds (≤9, ≤ 9.5, and ≤10).
RESULTS: At baseline, the participants' mean age was 35 years (SD ± 8), 53% were men, and 84% had less than a high school education. At baseline, sensitivity for detecting any HAND stage, symptomatic HAND [mild neurocognitive disorder, HAD], and HAD alone were maximized at IHDS ≤10 (81%, 83%, 92%, respectively). Among 312 individuals who returned for the 2-year follow-up and had initiated ART, a score of ≤10 provided a lower or equal sensitivity for detecting different stages of HAND (all HAND: 70%; symptomatic HAND: 75%; HAD: 94%). The area under the ROC curve was higher for ART-experienced versus ART-naïve individuals.
CONCLUSIONS: The IHDS is a potentially useful screening tool for neurocognitive impairment in rural Uganda for both ART-naïve and ART-experienced adults. A cutoff ≤10 demonstrates higher sensitivity for more severe HAND stages compared with less severe HAND. Future studies should focus on potential modifications to the IHDS to improve its specificity.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32032278      PMCID: PMC7197883          DOI: 10.1097/QAI.0000000000002257

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.771


  23 in total

1.  Self-report of symptoms and neuropsychological performance in asymptomatic HIV-positive individuals.

Authors:  S Beason-Hazen; H A Nasrallah; R A Bornstein
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1994       Impact factor: 2.198

2.  Neurocognitive impairment associated with predominantly early stage HIV infection in Abuja, Nigeria.

Authors:  Christopher Akolo; Walter Royal; Mariana Cherner; Kanayo Okwuasaba; Lindsay Eyzaguirre; Ruxton Adebiyi; Anya Umlauf; Terence Hendrix; Joyce Johnson; Alashl'e Abimiku; William A Blattner
Journal:  J Neurovirol       Date:  2014-06-14       Impact factor: 2.643

3.  HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.

Authors:  R K Heaton; D B Clifford; D R Franklin; S P Woods; C Ake; F Vaida; R J Ellis; S L Letendre; T D Marcotte; J H Atkinson; M Rivera-Mindt; O R Vigil; M J Taylor; A C Collier; C M Marra; B B Gelman; J C McArthur; S Morgello; D M Simpson; J A McCutchan; I Abramson; A Gamst; C Fennema-Notestine; T L Jernigan; J Wong; I Grant
Journal:  Neurology       Date:  2010-12-07       Impact factor: 9.910

4.  Validity of the International HIV dementia scale in Brazil.

Authors:  Roiza Almeida Rodrigues; Raquel Lisboa Oliveira; Beatriz Grinsztejn; Marcus Tulius T Silva
Journal:  Arq Neuropsiquiatr       Date:  2013-06       Impact factor: 1.420

Review 5.  HIV-associated neurocognitive disorder--pathogenesis and prospects for treatment.

Authors:  Deanna Saylor; Alex M Dickens; Ned Sacktor; Norman Haughey; Barbara Slusher; Mikhail Pletnikov; Joseph L Mankowski; Amanda Brown; David J Volsky; Justin C McArthur
Journal:  Nat Rev Neurol       Date:  2016-03-11       Impact factor: 42.937

6.  United States National Trends in Mortality, Length of Stay (LOS) and Associated Costs of Cognitive Impairment in HIV Population from 2005 to 2014.

Authors:  Smit Patel; Neil U Parikh; Ravikumar Aalinkeel; Jessica L Reynolds; Rashmi Dmello; Stanley A Schwartz; Supriya D Mahajan
Journal:  AIDS Behav       Date:  2018-10

7.  Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa.

Authors:  M H Wong; K Robertson; N Nakasujja; R Skolasky; S Musisi; E Katabira; J C McArthur; A Ronald; N Sacktor
Journal:  Neurology       Date:  2007-01-30       Impact factor: 9.910

8.  Clinical features and preliminary studies of virological correlates of neurocognitive impairment among HIV-infected individuals in Nigeria.

Authors:  Walter Royal; Mariana Cherner; Jean Carr; Abdulrazaq G Habib; Abimbola Akomolafe; Alashl'e Abimiku; Manhattan Charurat; John Farley; Akinwande Oluyemisi; Ibrahim Mamadu; Joyce Johnson; Ronald Ellis; J Allen McCutchan; J Allen McCutchen; Igor Grant; William A Blattner
Journal:  J Neurovirol       Date:  2012-04-18       Impact factor: 2.643

9.  Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study.

Authors:  Kathy Lawler; Mosepele Mosepele; Sarah Ratcliffe; Esther Seloilwe; Katherine Steele; Rudo Nthobatsang; Andrew Steenhoff
Journal:  J Int AIDS Soc       Date:  2010-04-20       Impact factor: 5.396

10.  HIV-associated neurocognitive disorders in sub-Saharan Africa: a pilot study in Cameroon.

Authors:  Georgette D Kanmogne; Callixte T Kuate; Lucette A Cysique; Julius Y Fonsah; Sabine Eta; Roland Doh; Dora M Njamnshi; Emilienne Nchindap; Donald R Franklin; Ronald J Ellis; John A McCutchan; Fidele Binam; Dora Mbanya; Robert K Heaton; Alfred K Njamnshi
Journal:  BMC Neurol       Date:  2010-07-13       Impact factor: 2.474

View more
  1 in total

1.  Screening Accuracy of Mini Addenbrooke's Cognitive Examination Test for HIV-Associated Neurocognitive Disorders in People Ageing with HIV.

Authors:  Mattia Trunfio; Davide De Francesco; Daniela Vai; Caterina Medina; Maurizio Milesi; Simone Domini; Chiara Alcantarini; Daniele Imperiale; Stefano Bonora; Giovanni Di Perri; Andrea Calcagno
Journal:  AIDS Behav       Date:  2022-01-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.